TransCode Therapeutics, Inc. (NASDAQ: RNAZ) has announced the appointment of Anna Moore, PhD, as Chair of its Scientific Advisory Board, along with the execution of a sponsored research agreement with Michigan State University. These developments are expected to accelerate the company's RNA-based therapeutic pipeline, with a focus on advancing its lead candidate, TTX-MC138, for the treatment of advanced cancers.
Dr. Moore, a renowned scientist in molecular imaging and nanomedicine, will provide strategic guidance on research and development efforts. Her expertise is anticipated to be instrumental in driving TransCode's programs forward, particularly in the area of immuno-oncology. The sponsored research agreement with Michigan State University will support the development of TTX-MC138, including its evaluation in combination with other therapies, potentially expanding its therapeutic applications.
TTX-MC138 targets metastatic tumors that overexpress microRNA-10b, a well-documented biomarker of metastasis. This approach addresses a critical unmet need in oncology, as metastatic disease is responsible for the majority of cancer-related deaths. TransCode's pipeline also includes other first-in-class therapeutic candidates designed to mobilize the immune system to recognize and destroy cancer cells.
The appointment of Dr. Moore and the collaboration with Michigan State University underscore TransCode's commitment to advancing its RNA-based therapies. These initiatives are expected to enhance the company's research capabilities and move its lead candidate closer to clinical application. For more details, the full press release is available at https://ibn.fm/NA2NH.
TransCode Therapeutics is a clinical-stage company pioneering RNA-based therapies for high-risk and advanced cancers. With a focus on treating metastatic disease, the company's lead candidate TTX-MC138 represents a novel approach to targeting microRNA-10b, a key driver of metastasis. The company's broader pipeline aims to harness the immune system to combat cancer, offering new hope for patients with limited treatment options.
These strategic moves are likely to strengthen TransCode's position in the competitive oncology landscape. By leveraging Dr. Moore's expertise and academic collaborations, the company aims to accelerate the development of its RNA-based platform and bring innovative treatments to patients in need. Investors and stakeholders can find the latest updates on TransCode in the company's newsroom at https://ibn.fm/RNAZ.
